{"slug":"olympus","name":"올림푸스","name_en":"Olympus","ticker":"7733.T","updated_at":"2026-10-13T17:25:44.083912+00:00","canonical":"https://valuechain.wiki/olympus","citable":"밸류체인 그래프 기준 올림푸스의 직접 연결 기업은 2곳(관계 기준 공급 2·매출 0)이고, 사슬을 2차까지 넓히면 5곳에 닿는다. 링크의 근거 출처는 9건이며 그중 1차공시가 2건이다 (valuechain.wiki, 2026-10-13 기준).","citable_en":"Per the valuechain.wiki graph, Olympus is directly linked to 2 companies (2 supply, 0 revenue relationships) and reaches 5 companies within two hops; the links are backed by 9 dated sources, 2 of them primary filings (as of 2026-10-13).","kicker":"소화기 내시경 · 외과·중재 솔루션 · 일회용 치료기기","kicker_en":"GI endoscopy · Surgical and interventional solutions · Single-use therapy devices","lead":"올림푸스는 소화기 내시경과 내시경 치료, 비뇨기·호흡기·외과 솔루션을 공급하는 일본 의료기기 기업이다. FY2027 1분기 매출은 2,404억엔으로 16.4% 늘었고 소화기 솔루션이 70%를 차지했다.","lead_en":"Olympus is a Japanese medical-device company supplying gastrointestinal endoscopy and endotherapy plus urology, respiratory and surgical solutions. FY2027 Q1 revenue rose 16.4% to JPY240.4 billion, with Gastrointestinal Solutions contributing 70%.","categories":[{"key":"medical-devices-supplies","ko":"의료기기·의료용품","en":"Medical Devices & Supplies","theme":"life-sciences","theme_ko":"바이오·헬스","theme_en":"Biopharma & Life Sciences","theme_kind":"sector","primary":true}],"segments":{"parts":[{"desc":"GI 내시경·치료기기·의료서비스","name":"소화기 솔루션","metric":"1,684억4,800만엔 (+21.2%, 70.1%)"},{"desc":"비뇨기·호흡기·외과내시경·기타 치료기기","name":"외과·중재 솔루션","metric":"719억2,300만엔 (+6.7%, 29.9%)"}],"total":"FY2027 1분기 연결매출 2,404억엔 (+16.4%)","track":"C","concentration":"개별 고객 매출 집중도는 공개하지 않음. 북미·유럽의 병원 및 의료기관 수요가 핵심"},"segments_en":{"parts":[{"desc":"GI endoscopy, endotherapy and medical services","name":"Gastrointestinal Solutions","metric":"JPY168.448 billion (+21.2%, 70.1%)"},{"desc":"Urology, respiratory, surgical endoscopy and other therapeutic devices","name":"Surgical & Interventional Solutions","metric":"JPY71.923 billion (+6.7%, 29.9%)"}],"total":"FY2027 Q1 consolidated revenue JPY240.4 billion (+16.4%)","track":"C","concentration":"No customer-level revenue concentration disclosed; hospital and care-provider demand in North America and Europe is central"},"returns_yearly":{"2021":35.5,"2022":-4.1,"2023":-8.8,"2024":8.5,"2025":-21.4,"2026":14.2},"return_asof":"2026-09-04","value_chain":{"leading":[],"benefiting":[{"slug":"dupont","name":"듀폰","name_en":"DuPont","tier":1,"returns_yearly":{"2021":15.4,"2022":-13.4,"2023":14.4,"2024":1,"2025":28.7,"2026":10.5}},{"slug":"canon","name":"캐논","name_en":"Canon","tier":1,"returns_yearly":{"2021":22.5,"2022":11.1,"2023":46.4,"2024":27,"2025":-3.2,"2026":2.4}},{"slug":"qnity-electronics","name":"퀴니티 일렉트로닉스","name_en":"Qnity Electronics","tier":2,"returns_yearly":{"2026":55.3}},{"slug":"international-flavors-fragrances","name":"인터내셔널 플레이버스 앤 프래그런스","name_en":"International Flavors & Fragrances","tier":2,"returns_yearly":{"2021":41.5,"2022":-28.3,"2023":-19.5,"2024":6.3,"2025":-18.4,"2026":27.5}},{"slug":"dai-nippon-printing","name":"다이닛폰인쇄","name_en":"Dai Nippon Printing","tier":2,"returns_yearly":{"2021":56.5,"2022":13.9,"2023":42.6,"2024":8.5,"2025":22.5,"2026":7.4}},{"slug":"hoya","name":"호야","name_en":"Hoya Corporation","tier":3,"returns_yearly":{"2021":10.8,"2022":-3,"2023":34.4,"2024":11.3,"2025":24.9,"2026":-2.5}}],"analysis":"올림푸스 주가는 2025년 21.4% 하락한 뒤 2026년 14.2% 반등했다. 같은 기간 의료포장 공급사 듀폰은 2025년 28.7%, 2026년 10.5% 올랐고, 초음파 시스템 공급 파트너 캐논은 2025년 3.2% 하락 후 2026년 2.4% 상승에 그쳤다. FY2027 1분기 올림푸스 매출이 16.4% 늘고 소화기 솔루션이 21.2% 성장했지만 수요 회복이 공급단 주가에 같은 속도로 전달되지는 않았다. 상대 위치는 후지필름의 2026년 13.6%와 비슷한 의료기기 반등 구간이다. 후행 구간은 캐논의 의료영상 노출이며, 듀폰은 포장 수요보다 Qnity 분사 효과와 산업재 포트폴리오가 수익률을 더 크게 좌우한다. 규제·품질 조치와 미국 관세가 실적 전파를 끊을 수 있는 예외다.","analysis_en":"Olympus shares fell 21.4% in 2025 and rebounded 14.2% in 2026. Medical-packaging supplier DuPont gained 28.7% in 2025 and 10.5% in 2026, while ultrasound-system partner Canon fell 3.2% in 2025 and rose only 2.4% in 2026. Olympus FY2027 Q1 revenue increased 16.4%, led by 21.2% growth in Gastrointestinal Solutions, but the demand recovery did not reach supplier equities at the same speed. Olympus sits close to Fujifilm Holdings, up 13.6% in 2026, in a medical-device rebound. Canon is the lagging listed link. DuPont is driven more by the Qnity separation and its mixed industrial portfolio than by packaging demand alone. Regulatory and quality actions plus U.S. tariffs are exceptions that can interrupt propagation.","analysis_asof":"2026-09-04"},"edges":[{"direction":"revenue","counterparty":"소화기 솔루션 고객 (병원·의료기관)","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"JPY_million","as_of":"2026-06-30","basis":"소화기 솔루션 부문 매출","value":168448,"period":"FY2027_Q1","basis_en":"Gastrointestinal Solutions revenue","qualifier":"reported"},"note":"내시경·내시경치료·서비스를 병원과 의료기관에 공급한다. FY2027 1분기 소화기 솔루션 매출은 1,684억4,800만엔으로 21.2% 증가했다.","note_en":"Olympus supplies endoscopy, endotherapy and services to hospitals and care providers. FY2027 Q1 Gastrointestinal Solutions revenue rose 21.2% to JPY168.448 billion.","sources":[{"stance":"confirms","publisher":"올림푸스","publisher_en":"Olympus Corporation","kind":"filing","lang":"en","published_at":"2026-08-07","url":"https://www.olympus-global.com/ir/data/brief/pdf/01_tanshin_Q1FY2027_en.pdf","title":"올림푸스 2027년 3월기 1분기 연결결산","title_en":"Consolidated Financial Results for the Three Months of FY2027","excerpt":"공시는 소화기 솔루션 1분기 매출 1,684억4,800만엔과 전년 대비 21.2% 증가를 보고했다.","excerpt_en":"The filing reports FY2027 Q1 Gastrointestinal Solutions revenue of JPY168.448 billion, up 21.2%."},{"stance":"mentions","publisher":"데일리팜","publisher_en":"Dailypharm","kind":"news","lang":"ko","published_at":"2026-07-08","url":"https://www.dailypharm.com/user/news/340215?view_mode=kakao","title":"올림푸스한국, 2300억 매출 회복, 수익성·치료 라인업 강화","title_en":"Olympus Korea revenue recovers to KRW 230 billion as profitability and therapy lineup strengthen","excerpt":"데일리팜은 올림푸스한국의 상품·서비스 매출이 함께 늘고 치료 솔루션이 확대됐다고 보도했다.","excerpt_en":"Dailypharm reports concurrent growth in Olympus Korea product and service sales and an expanding therapy portfolio."},{"stance":"mentions","publisher":"삼성증권","publisher_en":"Samsung Securities","kind":"research","lang":"ko","published_at":"2024-09-10","url":"https://www.samsungpop.com/common.do?cmd=down&contentType=application/pdf&fileName=2020/2024091010184252K_02_05.pdf&inlineYn=Y&saveKey=research.pdf","title":"의료기기: 소화기계 의료기기, 해외에서 먼저 알아본 경쟁력","title_en":"Medical devices: Korean gastrointestinal devices recognized overseas","excerpt":"삼성증권은 글로벌 내시경 장비 시장이 올림푸스 등 광학업체 중심의 과점 구조라고 분석했다.","excerpt_en":"Samsung Securities describes the endoscopy-equipment market as concentrated among optical-device leaders including Olympus."}]},{"direction":"cost","counterparty":"기타 부품·원재료 공급사 (비공개)","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"JPY_million","as_of":"2026-06-30","basis":"연결 매출원가, 듀폰·캐논 등 공개 공급관계 포함","value":83573,"period":"FY2027_Q1","basis_en":"consolidated cost of sales, including disclosed relationships such as DuPont and Canon","qualifier":"aggregate_not_supplier_specific"},"note":"공시는 개별 공급사별 매입액을 밝히지 않는다. FY2027 1분기 연결 매출원가는 835억7,300만엔으로 매출의 34.8%였다.","note_en":"The filing does not disclose purchases by individual supplier. FY2027 Q1 consolidated cost of sales was JPY83.573 billion, or 34.8% of revenue.","sources":[{"stance":"confirms","publisher":"올림푸스","publisher_en":"Olympus Corporation","kind":"filing","lang":"en","published_at":"2026-08-07","url":"https://www.olympus-global.com/ir/data/brief/pdf/01_tanshin_Q1FY2027_en.pdf","title":"올림푸스 2027년 3월기 1분기 연결결산","title_en":"Consolidated Financial Results for the Three Months of FY2027","excerpt":"공시는 1분기 매출원가 835억7,300만엔과 매출원가율 34.8%를 보고했지만 개별 공급사별 금액은 공개하지 않았다.","excerpt_en":"The filing reports Q1 cost of sales of JPY83.573 billion and a 34.8% cost ratio, without supplier-level amounts."}]},{"direction":"revenue","counterparty":"외과·중재 솔루션 고객 (병원·의료기관)","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"JPY_million","as_of":"2026-06-30","basis":"외과·중재 솔루션 부문 매출","value":71923,"period":"FY2027_Q1","basis_en":"Surgical & Interventional Solutions revenue","qualifier":"reported"},"note":"비뇨기·호흡기·외과내시경 제품을 병원과 의료기관에 공급한다. FY2027 1분기 부문 매출은 719억2,300만엔으로 6.7% 증가했다.","note_en":"Olympus supplies urology, respiratory and surgical-endoscopy products to hospitals and care providers. FY2027 Q1 division revenue rose 6.7% to JPY71.923 billion.","sources":[{"stance":"confirms","publisher":"올림푸스","publisher_en":"Olympus Corporation","kind":"filing","lang":"en","published_at":"2026-08-07","url":"https://www.olympus-global.com/ir/data/brief/pdf/01_tanshin_Q1FY2027_en.pdf","title":"올림푸스 2027년 3월기 1분기 연결결산","title_en":"Consolidated Financial Results for the Three Months of FY2027","excerpt":"공시는 외과·중재 솔루션 1분기 매출 719억2,300만엔과 전년 대비 6.7% 증가를 보고했다.","excerpt_en":"The filing reports FY2027 Q1 Surgical & Interventional Solutions revenue of JPY71.923 billion, up 6.7%."},{"stance":"mentions","publisher":"삼성증권","publisher_en":"Samsung Securities","kind":"research","lang":"ko","published_at":"2024-09-10","url":"https://www.samsungpop.com/common.do?cmd=down&contentType=application/pdf&fileName=2020/2024091010184252K_02_05.pdf&inlineYn=Y&saveKey=research.pdf","title":"의료기기: 소화기계 의료기기, 해외에서 먼저 알아본 경쟁력","title_en":"Medical devices: Korean gastrointestinal devices recognized overseas","excerpt":"삼성증권은 내시경·비혈관 스텐트·복강경이 최소침습 소화기 의료기기의 핵심 시장이라고 정리했다.","excerpt_en":"Samsung Securities identifies endoscopy, non-vascular stents and laparoscopy as core minimally invasive gastrointestinal-device markets."}]},{"direction":"investment","counterparty":"BioProtect","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD_million","as_of":"2026-06-01","basis":"BioProtect 지분 100% 인수비용(마일스톤 포함)","value":270,"period":"2026","basis_en":"cost to acquire 100% of BioProtect, including milestone payment","qualifier":"completed_acquisition"},"note":"올림푸스는 2026년 6월 BioProtect 지분 100%를 2억7,000만달러에 인수해 전립선암용 생분해성 직장 스페이서 사업을 편입했다.","note_en":"Olympus acquired 100% of BioProtect for $270 million in June 2026, adding biodegradable rectal spacers for prostate-cancer care.","sources":[{"stance":"confirms","publisher":"올림푸스","publisher_en":"Olympus Corporation","kind":"filing","lang":"en","published_at":"2026-06-02","url":"https://www.olympus-global.com/ir/data/announcement/2026/contents/ir00011.pdf","title":"BioProtect 지분 취득 완료 공시","title_en":"Notice Regarding Completion of Acquisition of BioProtect Ltd.","excerpt":"공시는 1,692만5,621주, 의결권 100%를 2억7,000만달러에 취득했다고 확인한다.","excerpt_en":"The filing confirms acquisition of 16,925,621 shares, representing 100% of voting rights, for $270 million."}]},{"direction":"cost","counterparty":"듀폰","counterparty_slug":"dupont","confidence":"high","metric":{"type":"count","unit":"device_categories","as_of":"2025-09-30","basis":"재생원료 타이벡을 적용하는 일회용 기기 범주","value":100,"period":"from_2026","basis_en":"single-use device categories adopting Tyvek with Renewable Attribution","qualifier":"more_than"},"note":"2026년부터 100개가 넘는 일회용 내시경 치료기기 범주의 멸균 포장에 듀폰 타이벡을 적용한다. 계약 금액은 공개되지 않았다.","note_en":"From 2026, Olympus is adopting DuPont Tyvek in sterile packaging for more than 100 single-use endotherapy device categories. Contract value is undisclosed.","sources":[{"stance":"confirms","publisher":"모르도르 인텔리전스","publisher_en":"Mordor Intelligence","kind":"research","lang":"ko","published_at":"2026-08-01","url":"https://www.mordorintelligence.kr/industry-reports/sterilization-pouches-market","title":"멸균 파우치 시장 규모, 점유율 및 2031년 성장 추세","title_en":"Sterilization Pouches Market Size, Share and Growth Trends to 2031","excerpt":"모르도르 인텔리전스는 올림푸스가 2026년부터 일본·베트남에서 100개 이상 기기 범주에 듀폰 타이벡을 적용한다고 확인했다.","excerpt_en":"Mordor Intelligence confirms Olympus adoption of DuPont Tyvek across more than 100 device categories in Japan and Vietnam from 2026."},{"stance":"confirms","publisher":"듀폰","publisher_en":"DuPont","kind":"ir","lang":"en","published_at":"2026-04-03","url":"https://www.dupont.com/knowledge/delivering-sustainable-innovation-for-sterile-packaging.html","title":"올림푸스의 재생원료 타이벡 채택 사례","title_en":"Delivering sustainable innovation for sterile packaging","excerpt":"듀폰은 올림푸스가 기존 공급채널을 통해 재생원료 타이벡을 구매한다고 설명했다.","excerpt_en":"DuPont says Olympus purchases Tyvek with Renewable Attribution through existing supply channels."},{"stance":"confirms","publisher":"올림푸스","publisher_en":"Olympus Corporation","kind":"ir","lang":"en","published_at":"2025-09-30","url":"https://www.olympus-global.com/news/2025/nr02905.html","title":"올림푸스, 듀폰 재생원료 타이벡을 멸균 포장에 채택","title_en":"Olympus Commits to Advancing Sustainable Packaging Enabled by DuPont Tyvek with Renewable Attribution","excerpt":"올림푸스는 일본과 베트남 생산시설에서 100개가 넘는 일회용 기기 범주의 멸균 포장에 듀폰 타이벡을 적용한다고 발표했다.","excerpt_en":"Olympus says it will use DuPont Tyvek in sterile packaging for more than 100 single-use device categories at plants in Japan and Vietnam."}]},{"direction":"cost","counterparty":"캐논","counterparty_slug":"canon","confidence":"high","metric":{"type":"relationship","as_of":"2026-04-08","basis":"캐논메디칼이 개발·제조하고 올림푸스가 판매·마케팅하는 Aplio i800 EUS","period":"since_2024","basis_en":"Aplio i800 EUS developed and manufactured by Canon Medical and sold and marketed by Olympus","qualifier":"confirmed_no_disclosed_value"},"note":"캐논메디칼이 Aplio i800 EUS 초음파 진단장치를 개발·제조하고 올림푸스가 자사 초음파내시경과 묶어 판매·마케팅한다. 거래 금액은 공개되지 않았다.","note_en":"Canon Medical develops and manufactures the Aplio i800 EUS ultrasound system, while Olympus sells and markets it with Olympus ultrasound endoscopes. Transaction value is undisclosed.","sources":[{"stance":"confirms","publisher":"메디칼타임즈","publisher_en":"Medical Times","kind":"news","lang":"ko","published_at":"2026-04-08","url":"https://medicaltimes.com/Main/News/NewsView.html?ID=1168143","title":"공동전선 구축한 캐논+올림푸스, 내시경 초음파 시장 조준","title_en":"Canon and Olympus jointly target the endoscopic ultrasound market","excerpt":"메디칼타임즈는 양사의 첫 공동 제품 Aplio i800 EUS가 2026년 미국 시장에도 출시됐다고 확인했다.","excerpt_en":"Medical Times confirms that the partners launched their first joint product, Aplio i800 EUS, in the U.S. in 2026."},{"stance":"confirms","publisher":"올림푸스","publisher_en":"Olympus Corporation","kind":"ir","lang":"en","published_at":"2024-01-15","url":"https://www.olympus-global.com/news/2024/nr02606.html","title":"캐논메디칼과 올림푸스의 내시경 초음파 시스템 사업 제휴","title_en":"Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems","excerpt":"공식 제휴는 캐논메디칼이 진단 초음파 시스템을 개발·제조하고 올림푸스가 판매·마케팅한다고 명시한다.","excerpt_en":"The official alliance states that Canon Medical develops and manufactures the diagnostic ultrasound system and Olympus handles sales and marketing."}]}]}